ANEMIA IN PATIENTS WITH CHRONIC HEART FAILURE


Citar

Texto integral

Resumo

The review provides data for the prevalence and pathogenesis of anemia in patients with chronic heart failure (CHF), its impact on the disease and the prognosis for these patients. According to some reports, the prevalence of anemia in patients with CHF amounts to 50%. Anemia increases mortality in patients with CHF and is accompanied by more frequent rehospitalization, as well as increases severity and contributes to the progression of the underlying disease. In CHF, pathogenetic mechanisms of anemia are complex and may be associated with iron deficiency, erythropoietin deficiency, redistribution of iron (anemia of chronic disease), and several other factors, which must be considered in the management of CHF patients with anemia.

Bibliografia

  1. Amsterdam P.B. Comprehensive Cardiovascular Medicine. Philadelphia, PA: Lippincott-Raven; 1998
  2. Преображенский Д.В., Воробьев П.А., Некрасова Н.И. и соавт. Анемия у больных с хронической сердечной недостаточностью: распространенность и клиническое значение // Клин. геронтол. 2005. № 10. С. 40-3
  3. Ezekowitz J, McAlister F, Armstrong P. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with newonset heart failure. Circulation 2003;107(2):223-25.
  4. Ryan E, Devlin M, Prendiville T, et al. The Prevalence and Natural History of Anaemia in an Optimally Treated Heart Failure Population. Br J Cardiol 2004;11(5):369-75.
  5. Nanas J, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006;48(12):2485-89.
  6. Witte K, Desilva R, Chattopadhyay S, et al. Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J 2004;147:924-30.
  7. Cromie N, Lee C, Struthers AD. Anaemia in chronic heart failure what is its frequency in the UK and its underlying causes? Heart 2002;87:377-78.
  8. Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005;26:2232-37.
  9. de Silva R, Rigby AS, Witte KK, et al. Anemia, renal dysfunction and their interaction in patients with chronic heart failure. Am J Cardiol 2006;98:391-98.
  10. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-23.
  11. Bauer C, Kurtz A. Oxygen sensing in the kidney and its relation to erythropoietin production. Annu Rev Physiol 1989;51:845-56.
  12. Jensen JD, Eiskjaer H, Bagger JP, et al. Elevated level of erythropoietin in congestive heart failure: relationship to renal perfusion and plasma rennin. J Intern Med 1993;233:125-30.
  13. Volpe M, Tritto C, Testa U, et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, andhormonal profiles. Am J Cardiol 1994;74:468-73.
  14. Donnelly S. Why is erythropoietin made in the kidney? The kidney functions as a critmeter. Am J Kidney Dis 2001;38:415-25.
  15. Anand IS, Ferrari R, Kalra GS, et al. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 1989;80:299-305.
  16. Anand IS. Pathogenesis of anemia in cardiorenal disease. Rev Cardiovasc Med 2005;6(3):13-21.
  17. Katz SD. Mechanisms and treatment of anemia in chronic heart failure. Congest Heart Fail 2004;10:243-7.
  18. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood 1999;94:1864-77.
  19. Mrug M, Stopka T, Julian BA, et al. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997;100:2310-14.
  20. Ishani A, Weinhandl E, Zhao Z, et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2005;45:391-9.
  21. Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 2005;112:1121-7.
  22. Fyhrquist F, Karppinen K, Honkanen T, et al. High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril. J Intern Med 1989;226:257-60.
  23. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005;112:1428-34.
  24. Anand IS, Rector T, Deswal A, et al. Relationship between proinflammatory cytokines and anemia in heart failure. Eur Heart J 2006;27(1):485.
  25. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998;18:555-59.
  26. Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002;17(11):39-43.
  27. Gaetano C, Locati M, Mantovani A. Control of iron homeostasis as a key component of macrophage polarization. Нaematologica 2010;95(11):1801-03.
  28. Horwich TB, Fonarow GC, Michele A. Hamilton et al. Anemia Is Associated With Worse Symptoms, Greater Impairment in Functional Capacity and a Significant Increase in Mortality in Patients With Advanced Heart Failure. J Am Coll Cardiol 2002;39:1780-86.
  29. Tang WHW, Tong W, Jain A, et al. Evaluation and Long-Term Prognosis of New-Onset, Transient, and Persistent Anemia in Ambulatory Patients With Chronic Heart Failure. J Am Coll Cardiol 2008;51:569-76.
  30. Kosiborod M, Curtis P, Wang Y, et al. Anemia and Outcomes in Patients With Heart Failure. Arch Intern Med 2005;165;2237-44.
  31. Kannel W. Epidemiology and prevention of cardiac failure. Framingham Study insights. Eur Heart J 1987;8:23-9.
  32. Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J 1993;70:357-62.
  33. Olivetti G, Quaini F, Lagrasta C, et al. Myocyte cellular hypertrophy and hyperplasia contribute to ventricular wall remodeling in anemiainduced cardiac hypertrophy in rats. Am J Pathol 1992;141:227-39.
  34. Levin A. The treatment of anemia in chronic kidney disease: understandings in 2006. Curr Opin Nephrol Hypertens 2007;16:267-71.
  35. Anand IS, McMurray JJ, Whitmore J, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004;110:149-54.
  36. Гончарова Е.В., Говорин А.В., Кузьмин А.Г, Баркан В.С., Филев А.П. Структурно-функциональные показатели миокарда у больных хронической железодефицитной анемией // Кардиология 2008. Ò. 48. С. 46-50.
  37. Дворецкий Л.И., Желнов В.В., Дятлов Н.В. Клиническое значение анемии у больных сердечной недостаточностью // Сеченовский вестник 2010. № 2. С. 56-60.
  38. Packer M, Carver JR, et al. Effect of oral milrinone on mortality in severe chronic heart failure. En J Med 1991;325(21):1468-75.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2011

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies